Scholarship applications are now closed
The winner will be notified by 16 March 2018.
NMS 2018 is pleased to be offering the Asia-Pacific Quality Use of Medicines (QUM) Scholarship again.
This scholarship provides the opportunity for an academic, health worker or policy maker from the Asia-Pacific region with an interest in quality use of medicines or rational drug use to attend and present their work at NMS 2018.
The scholarship provides complimentary registration for NMS 2018. The winner will provide a 15-minute oral presentation of their work at the symposium.
The winner of the 2016 scholarship was Wong Zhi Yen from Perak, Malaysia, who presented a comprehensive perspective of the challenges, opportunities and future outlook of the Malaysian generic market.
Read his abstract.Toggle information
Malaysian generic market: Challenges, opportunities and future outlook
Wong Zhi Yen, Perak, Malaysia
Introduction: In the challenging scenario of health care provision, one of the mechanisms suggested to slow the rapid growth of pharmaceutical expenditure is the greater use of generic medicines. However, the Malaysian prescription market is still dominated by patented drugs despite the continuous efforts to increase the generic utilization rate. Malaysian pharmaceutical stakeholders consist of policymakers, pharmaceutical manufacturers, doctors, pharmacists and consumers. Different stakeholders might have different perspectives, perceptions and views about generic medicines.
Objective: The objectives were to provide a comprehensive compilation of the published literature related to healthcare stakeholders’ knowledge, attitudes, views and perceptions towards generic medicines or generic substitution in Malaysia and to suggest recommendations to improve generic medicines utilization according to different healthcare stakeholders’ need.
Methods: A systematic search of articles published in peer-reviewed journals from January 2001 to November 2013 was performed. The search used 11 electronic databases. The search strategy involved using Boolean operators for combinations of the following keywords: generic AND Malaysia, Malaysia AND pharmaceutical, Malaysia AND Medicine Policy, Malaysia AND Economic Transformation.
Key findings: Twelve articles were included in this review. Two studies were conducted with generic manufacturers, one study with medical practitioners, six studies with community pharmacists and three studies with medicine consumers. Generic manufacturers expressed some concerns about the generic medicines policy and drug approval system in Malaysia. In addition, medical practitioners, pharmacists and medicine consumers still have misconceptions about safety, quality, efficacy and bioequivalence of generic medicines. Furthermore, despite the availability of some pro-generic policies, there is a lack of effective implementation of these policies in the country.
Conclusion: Different healthcare stakeholders have different concerns and views towards generic medicines as well as different levels of knowledge about them. The existing generic medicines policy and Economic Transformation Program should be implemented as planned. Educational and promotional campaigns should be carried out to improve utilization of generic medicines among all healthcare stakeholders in Malaysia.
Keywords: generic medicine; generic pharmaceutical industry; healthcare stakeholder; Malaysia; perspective
To be eligible, applicants must meet these general eligibility requirements:
- Tertiary qualifications
- Strong written and spoken English language skills
- At least four years of work experience
- Citizen of and residing in an eligible country (see table below)
Federated States of Micronesia
Papua New Guinea
Wallis & Futuna
(West) Papua/Irian Jaya
Applications are now closed. The winner will be notified by 16 March 2018.